Stroke survivors and recent surgical patients face an elevated risk of blood clot formation in the lower legs, as decreased mobility diminishes the ability of the body's natural compression system to pump blood out of deep leg veins. Low compliance rates, discomfort, and limited effectiveness detract from external compression, the current standard of clot prevention, leading Sky Medical to meet the market's need with a bioelectronic device that electrically stimulates motor neurons.Subscribe now to read the full analysis
Welcome to MyStrategist, an online experience like no other in the medical device industry.
With MyStrategist, quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and MedTech Strategist Market Pathways – now on an all-in-one, digital platform. We invite you to explore our coverage.
Think Strategically. Subscribe Today.
Registration is now open for the 7th annual Innovation Summit Dublin, April 21-23, 2020. The industry's most anticipated event will sell out. Register Today.Register Learn More
FDA’s device program increase stands out in the Trump administration’s 2021 budget request. More policies to watch in the budget, and developments in India, China, Malaysia, and Australia in this week’s Pathways’ Picks, Market Pathways’ weekly roundup of the most important global medtech regulatory, reimbursement, and policy news.Subscribe now to read the full analysis
Addressing a Global Health Emergency: Tips on Applying to FDA for a Novel Coronavirus Diagnostic EUA
Novel Device Approval Numbers Drop Sharply, But All is Well, FDA's Shuren Says
Pathways’ Picks February 19: Coronavirus Cancellations, EU Digital, NICE on Neurostim
Our strategic publications provide actionable intelligence to support each member of your organization. Check to see if your company has access.Learn More
FDA’s device program increase stands out in the Trump administration’s latest budget request. That and a few other policy proposals to watch from the budget in this week’s top news pick from Market Pathways.Subscribe now to read the full analysis